Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis

Susan Yount*, Mark V. Sorensen, David Cella, Nishan Sengupta, James Grober, Elliot K. Chartash

*Corresponding author for this work

Research output: Contribution to journalArticle

53 Scopus citations

Fingerprint Dive into the research topics of 'Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis'. Together they form a unique fingerprint.

Medicine & Life Sciences